Celcuity ( (CELC) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Celcuity shares are under pressure as investors reassess how much of the recent optimism was already priced in, despite strong clinical news. Some traders appear to be taking profits after an earlier rally, adding to the downside move.
The company recently reported positive topline results from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 breast cancer trial, meeting its primary endpoint for progression-free survival. Analysts had lifted their targets after the data and the FDA’s Priority Review for the wild-type cohort, but expectations may now be resetting.
Celcuity is preparing a supplemental New Drug Application for its drug candidate, backed by success in both gedatolisib triplet and doublet regimens. The stock’s pullback suggests the market is questioning how quickly these clinical wins will translate into commercial profits and long-term valuation gains.
More about Celcuity
YTD Price Performance: 25.98%
Average Trading Volume: 748,856
Technical Sentiment Signal: Buy
Current Market Cap: $6.07B
For further insights into CELC stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.